Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Formycon: H1 2026 revenue nearly tripled, adjusted EBITDA significantly improved

Formycon reports that first-half 2026 revenue nearly tripled year-on-year and adjusted EBITDA improved to -6.9 Mio. EUR (previously -19.2 Mio. EUR). Drivers were milestone payments (14.3 Mio. EUR) and stronger commercial sales, with FYB206 accounting for more than 40% of revenue. Cash resources fell to 51.8 Mio. EUR, and total assets amount to 714 Mio. EUR. Management confirmed the full-year guidance but warned of non-linear revenue timing and competitive risks in the biosimilar market. » Mais em de.investing.com
Formycon raises half‑year revenue to €25.8m and reduces EBITDA loss

Formycon reports H1 2026 revenue of €25.8m and a reduced EBITDA loss of €3.4m. Growth was driven by milestone and advance payments from partnerships for FYB206 as well as increased licensing income and milestone payments from FYB202. Lower research and development costs due to project progress and capitalization of development expenses contributed to the improved results. Formycon confirmed its full‑year guidance of €60–70m revenue and group EBITDA of €0–10m and completed the clinical development of FYB206. » Mais em de.investing.com
Formycon improves preliminary results for fiscal year 2025 and schedules audited annual financial statements

Formycon reports a significant improvement in its preliminary operating figures for 2025: group EBITDA improves from -€12m to around -€4m, and group adjusted EBITDA from -€7m to around -€2m. Group revenue remains unchanged at around €45m. Group working capital is about €70m (previously ~€73m, guidance €55–65m). Publication of the audited annual financial statements and an analyst conference are scheduled for 22 April 2026. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, Formycon já distribuiu € 0,26 em dividendos. A última distribuição ocorreu em março de 2022.

Dados financeiros da empresa

No último trimestre, Formycon registou receitas de € 25,76 mi e um ganho líquido de -€ 14,63 mi

(EUR)	junho de 2026	YoY
Receitas	25,76 mi	-
Ganho bruto	-3,04 mi	-
Ganho líquido	-14,63 mi	-
EBITDA	-4,98 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 363,18 mi
Número de ações	17,67 mi
Máximo/mínimo de 52 semanas	€ 80,20 - € 20,25
Dividendos	Não
Beta	0,72
PER (PE Ratio)	-14,51
PEG (PEG Ratio)	-0,09
P/VC (PB Ratio)	0,94
P/V (PS Ratio)	5,94

Perfil da empresa

Die Formycon AG entwickelt und vermarktet Biosimilar-Produkte. Die Produktpipeline umfasst FYB201, einen Biosimilar-Kandidaten für Lucentis, ein Augenarzneimittel, das zur Behandlung der neovaskulären altersbedingten Makuladegeneration und anderer schwerer Augenerkrankungen eingesetzt wird; FYB202, ein Biosimilar-Kandidat für Stelara, ein Biopharmazeutikum, das zur Behandlung von Entzündungskrankheiten wie mittelschwerer bis schwerer Schuppenflechte sowie zur Behandlung von Morbus Crohn und Colitis ulcerosa eingesetzt wird und sich in der klinischen Prüfung der Phase III befindet; und FYB203, ein Biosimilar-Kandidat für Eylea zur Behandlung der neovaskulären altersbedingten Makuladegeneration und anderer Augenkrankheiten, der sich in der klinischen Prüfung der Phase III befindet. Das Unternehmen entwickelt außerdem FYB206 und FYB207, ein antivirales Medikament zur Behandlung von COVID-19. Es hat eine Kooperationsvereinbarung mit der Leukocare AG zur Entwicklung stabiler Formulierungen für verschiedene Kandidaten in seiner Produktpipeline. Das Unternehmen war früher unter dem Namen Nanohale AG bekannt und änderte 2012 seinen Namen in Formycon AG. Die Formycon AG wurde 1999 gegründet und hat ihren Hauptsitz in Planegg, Deutschland.

Nome	Formycon
CEO	Stefan Glombitza
Sede	Planegg, bv Alemanha
Site	formycon.com
Setor	Cuidados de saúde
Indústria	Produtos farmacêuticos
Entrada em bolsa	04/01/2011
Colaboradores	203